Patents Assigned to Hadasit Medical Research Services and Development Ltd.
  • Patent number: 8986929
    Abstract: The present invention identifies genotypes associated with resistance to extrapyramidal symptoms induced by antipsychotic drugs. The present invention further identifies genotypes associated with predisposition to the onset or aggravation of extrapyramidal symptoms induced by antipsychotic drugs and use thereof for assessment of patient populations. Specifically, the present invention relates to particular polymorphisms in the RGS2 gene that are associated with resistance or susceptibility to drug-induced extrapyramidal symptoms.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: March 24, 2015
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Bernard Lerer, Lior Greenbaum
  • Patent number: 8980244
    Abstract: The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: March 17, 2015
    Assignees: Ben-Gurion University of the Negev Research and Development Authority, Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.
    Inventors: Ofer Mandelboim, Angel Porgador, Yaakov Naparstek, Chamutal Gur
  • Patent number: 8975294
    Abstract: The present invention relates to methods kits and combined compositions using DFO-metal complexes, specifically, Zinc-desferrioxamine (Zn-DFO), gallium-desferrioxamine (Ga-DFO) complexes and any combinations thereof for preventing, treating, ameliorating or inhibiting an immune-related disorder, specifically, a skin-related inflammatory disorder such as psoriasis, an inflammatory respiratory condition such as asthma, and an autoimmune disease such as diabetes and any immune-related disorder.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: March 10, 2015
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Mordechai Chevion, Vladimir Vinokur, Eduard Berenshtein, Ron Eliashar, Baruch Bulvik
  • Patent number: 8956866
    Abstract: The present invention concerns RPE cells obtainable by directed differentiation from stem cell, particularly, human stem cells. It has been specifically found that culturing stem cells in the presence of one or more member of the TGF? superfamily, such as Activin A) induced directed differentiation into mature and functional RPE cells. This was evidenced by the expression of markers specific to mature RPE cells, including MiTF-A, RPE65 or Bestrophin). In accordance with one particular embodiment, the cells are a priori cultured with nicotinamide (NA) which was found to augment the cells' response to the inductive effect of the one or more member of the TGF? superfamily. The invention also provides methods of performing the directed differentiation, as well as methods for use of the resulting RPE cells.
    Type: Grant
    Filed: April 27, 2008
    Date of Patent: February 17, 2015
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Masha Idelson, Ruslana Alper-Pinus, Alex Obolensky, Eyal Banin, Benjamin Reubinoff
  • Publication number: 20140341952
    Abstract: A method for treating a disease comprising administering to a mammal in need thereof an effective dosage of an extract of a plant of the genus Hoodia, wherein the disease is selected from the group consisting of immune-mediated disorders, immune-associated disorders, inflammatory diseases, coronary disease, insulin resistance and liver-related diseases. In a preferred embodiment, the Hoodia is Hoodia parviflora. Also disclosed is a pharmaceutical composition for treating the above diseases comprising an effective dosage of an extract of a plant of the genus Hoodia.
    Type: Application
    Filed: December 19, 2013
    Publication date: November 20, 2014
    Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD., BIO-MASS LTD., DESERT LABS AGRICULTURE COOPERATIVE ASSOCIATION LTD.
    Inventors: Refael Aharon, Yaron Ilan
  • Patent number: 8868194
    Abstract: The present invention depicts an implantable artificial pacemaker (AAP) comprising oscillatory means providing pulsating signals at a pre-selected frequency, wherein the pacemaker is pacing the aorta. The invention also describes an AAP further comprising; (i) a plurality of sensors disposed internally or externally to the aorta; and (ii) a pacing means in which the AAP stimulates the aortic media, augmenting physiological aortic elastic recoil. An AAP further comprising a processor capable of obtaining information from sensors and triggering an appropriate contraction wave in the aortic media is also introduced. A method of managing aortic rhythm comprising; (i) implanting an AAP comprising oscillatory means; and (ii) pulsating signals at a preselected frequency, so as to pace the aorta and in which the pulsating signals are provided by synchronizing and coordinating activation impulses in a portion of the aorta using electrical impulses is also taught.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: October 21, 2014
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Amos Cahan, David Planer
  • Patent number: 8865909
    Abstract: Novel agents exhibiting anti-biofilm formation activity while being non-cytotoxic are provided, as well as methods of using the same, either per se or conjugated to a polymer, for preventing and/or reducing the formation of microbial biofilms and/or for disrupting microbial biofilms. The novel agents described herein include thiazolidine-2,4-diones (TZDs), pyrrolidine-2,5-diones (PYDs), imidazolidine-2,4-diones or oxazolidine-2,4-diones, substituted by an alkyl having 7-20 carbon atoms in its backbone chain.
    Type: Grant
    Filed: November 19, 2009
    Date of Patent: October 21, 2014
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventors: Morris Srebnik, Itzhack Polacheck, Doron Steinberg, Adel Jabbour, Edward Sionov
  • Publication number: 20140255403
    Abstract: This application describes a method of delivering a TNF antagonist molecule, in a biologically active form, to a subject in need thereof, the method comprising, orally or mucosally administering to the subject a therapeutically effective amount of a TNF antagonist molecule. This application further describes a method of treating, preventing or reducing the severity of obesity, the method comprising, administering to the subject a therapeutically effective amount of a TNF antagonist molecule.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 11, 2014
    Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventor: Yaron ILAN
  • Publication number: 20140255420
    Abstract: The present invention relates to a combination therapy for the treatment of immune-related disorders. More particularly, the invention relates to oral or mucosal synergistic compositions combining beta-glycolipids, preferably, ?-glycosphin-golipids with immunoglobulin molecules specific for at least one antigen derived from a component of the immune system, specifically an anti-CD3 antibody. The invention further provides methods kits and uses of the combined compositions of the invention for immune-modulation and thereby for the treatment of immune-related disorders. In a preferred embodiment, anti-CD3 antibody (OKT3) is orally administered in combination with ?-glucosylceramide (also known as glycocerebroside) in an animal model of type 2 diabetes.
    Type: Application
    Filed: February 18, 2014
    Publication date: September 11, 2014
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Yaron Ilan, Howard L. Weiner
  • Patent number: 8804904
    Abstract: A physical phantom reference to control for variability of computed tomography measurement results duplicates the density curve of blood perfusion of contrast material in a healthy aorta or large artery to normalize observed changes in healthy arterial blood perfusion when calculating the reduction in tumor blood perfusion between two examination times. In one embodiment, a plurality of compartments with different concentrations of contrast material corresponding to a density curve of blood perfusion of a healthy tissue are positioned-in a screening field of a CT machine so the CT machine images the compartments when it images the healthy tissue. In another embodiment, a pipe containing fluid receives an injection of contrast material from the injector when the injector injects the contrast material into the patient, the pipe having sections of varying diameter so the sections together correspond to a blood perfusion curve of the contrast material in a healthy tissue.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: August 12, 2014
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Aviv Hirschenbain, Jacob Sosna
  • Publication number: 20140114176
    Abstract: A physical phantom reference to control for variability of computed tomography measurement results duplicates the density curve of blood perfusion of contrast material in a healthy aorta or large artery to normalize observed changes in healthy arterial blood perfusion when calculating the reduction in tumor blood perfusion between two examination times. In one embodiment, a plurality of compartments with different concentrations of contrast material corresponding to a density curve of blood perfusion of a healthy tissue are positioned-in a screening field of a CT machine so the CT machine images the compartments when it linages the healthy tissue. In another embodiment, a pipe containing fluid receives an injection of contrast material from the injector when the injector injects the contrast material into the patient, the pipe having sections of varying diameter so the sections together correspond to a blood perfusion curve of the contrast material in a healthy tissue.
    Type: Application
    Filed: December 24, 2013
    Publication date: April 24, 2014
    Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD
    Inventors: Aviv HIRSCHENBAIN, Jacob SOSNA
  • Patent number: 8686041
    Abstract: The invention relates to inhibition of ornithine aminotransferase (OAT) for suppression of tumor cells proliferation. More particularly, the invention relates to methods of treatment of proliferative disorders by the selective inhibition of OAT, and further provides the use of OAT inhibitors, specifically, 5-amino-1,3-hexadienyl-carboxylic acid (Gabaculine), and Gabaculine analogue 8, for compositions and methods for the treatment of proliferative disorders such as hepatocellular carcinoma. The invention further provides methods and kits for the diagnosis of a pathologic proliferative disorder in a mammalian subject, based on determining the level of OAT expressed in a biological sample obtained from a subject.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: April 1, 2014
    Assignees: Hadasit Medical Research Services & Development, Ltd., Northwestern University
    Inventors: Yaron Ilan, Ehud Zigmond, Richard B. Silverman, Hejun Lu
  • Patent number: 8680148
    Abstract: Methods for treating a bacterial infection by using a metallo-desferrioxamine complex.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: March 25, 2014
    Assignees: University of Washington, Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: E. Peter Greenberg, Ehud Banin, Eyal Banin, Eduard Berenshtein, Mordechai Chevion
  • Publication number: 20140080782
    Abstract: A method of diagnosing pancreatic cancer in a subject is provided. The method comprising determining a level and/or activity of at least one saliva secreted marker in a saliva sample of the subject wherein an alteration in said marker with respect to an unaffected saliva sample is indicative of the pancreatic cancer.
    Type: Application
    Filed: December 13, 2011
    Publication date: March 20, 2014
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Aaron Palmon, Omer Deutsch, Doron Aframian, Oren Lahav
  • Patent number: 8636411
    Abstract: A physical phantom reference to control for variability of computed tomography measurement results duplicates the density curve of blood perfusion of contrast material in a healthy aorta or large artery to normalize observed changes in healthy arterial blood perfusion when calculating the reduction in tumor blood perfusion between two examination times. In one embodiment, a plurality of compartments with different concentrations of contrast material corresponding to a density curve of blood perfusion of a healthy tissue are positioned-in a screening field of a CT machine so the CT machine images the compartments when it images the healthy tissue. In another embodiment, a pipe containing fluid receives an injection of contrast material from the injector when the injector injects the contrast material into the patient, the pipe having sections of varying diameter so the sections together correspond to a blood perfusion curve of the contrast material in a healthy tissue.
    Type: Grant
    Filed: February 3, 2010
    Date of Patent: January 28, 2014
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Jacob Sosna, Aviv Hirschenbain
  • Patent number: 8617561
    Abstract: An article of manufacture comprising packaging material and a pharmaceutical composition is disclosed, the article of manufacture being identified in print in or on the packaging material for treatment of an immunity-related disease in a subject in need thereof. The pharmaceutical composition comprises a pharmaceutically acceptable carrier and, as an active ingredient, a compound being capable of modulating an interaction between a heparin-binding domain of a thrombospondin and a receptor of the heparin-binding domain.
    Type: Grant
    Filed: June 20, 2006
    Date of Patent: December 31, 2013
    Assignees: Hadasit Medical Research Services and Development Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Dror Mevorach, Alon Krispin, Yaniv Bledi, Michal Linial
  • Publication number: 20130314669
    Abstract: A method of diagnosis is disclosed. The method comprises using a display device for presenting a motion perception test to a subject and determining a subject response to the motion perception test. The response can be used for assessing presence or absence of demyelination and/or remyelination.
    Type: Application
    Filed: October 18, 2012
    Publication date: November 28, 2013
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Netta LEVIN, Noa Raz, Tamir Ben-Hur
  • Patent number: 8575307
    Abstract: The present invention provides peptides and peptide analogs capable of inhibiting the activity of protein kinase C. The invention discloses use of such peptides and analogs for preparation of pharmaceutical compositions and methods for prevention, delay, suppression or treatment of type 2 diabetes using such compositions.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: November 5, 2013
    Assignee: Hadasit Medical Research Services & Development Ltd.
    Inventors: Eleazar Shafrir, Ehud Ziv, Hadas Reuveni, Masha Niv
  • Publication number: 20130245618
    Abstract: A highly controlled and precise system, device and method for tissue and cellular alteration and treatment below or at surfaces with a laser. The present invention is characterized by ultra low levels of collateral damage as defined by physiologically relevant tests that measure tissue viability. The operation of the present invention is based on spectrally confining the interaction between laser energy and a targeted tissue including an essential element for physiologically relevant tests for monitoring tissue viability.
    Type: Application
    Filed: May 6, 2013
    Publication date: September 19, 2013
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Eithan GALUN, Aaron Lewis, Evelyne Zeira, Alexandra Manevitch, Artium Khatchatouriants, Yitzchak Hemo
  • Publication number: 20130202724
    Abstract: The invention provides methods and uses of different soybean extracts, for example, enzymatic, hexane, ethanol or aqueous soybean extracts and combinations thereof for the treatment of hepatic disorders, drug induced hepatic injury, the Metabolic Syndrome or an immune-related disorder in a subject in need thereof. The invention further provides pharmaceutical compositions, kits and methods thereof for treating and preventing hepatic disorders.
    Type: Application
    Filed: August 4, 2011
    Publication date: August 8, 2013
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventor: Yaron Ilan